GPT and rheumatoid arthritis: In a recent pooled safety analysis of IV golimumab across the three aforementioned Phase 3 studies of patients with RA, PsA, and AS (N = 1248), concomitant MTX use was associated with a higher occurrence of elevated alanine transaminases (from ≥ 3 to < 5 times the upper limit of normal) compared with golimumab without MTX [36].